Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.67 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 4/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | POLB | P06746 | 3/20 | 0.65 |
| ▸ | MAPT | P10636 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.65 |
| ▸ | HTT | P42858 | 1/20 | 0.65 |
| ▸ | RAD52 | P43351 | 1/20 | 0.65 |
| ▸ | RECQL | P46063 | 1/20 | 0.65 |
| ▸ | RAB9A | P51151 | 1/20 | 0.65 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.65 |
| ▸ | CA12 | O43570 | 3/20 | 0.60 |
| ▸ | CA1 | P00915 | 3/20 | 0.60 |
| ▸ | CA2 | P00918 | 3/20 | 0.60 |
| ▸ | CA9 | Q16790 | 3/20 | 0.60 |
| ▸ | LCK | P06239 | 1/20 | 0.59 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.55 |
| ▸ | NGFR | P08138 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10688641 | 0.87 | FTO (0.60) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL9501871 | 0.86 | MEN1 (0.79) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL14560564 | 0.86 | FTO (0.73) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL3861437 | 0.86 | FTO (0.69) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL10687035 | 0.85 | FTO (0.60) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL12502144 | 0.85 | FTO (0.75) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL14557199 | 0.83 | MEN1 (0.85) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL1893251 | 0.83 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL2285573 | 0.83 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB | |
| SCHEMBL1901643 | 0.83 | FTO (0.72) | FTOPABPC1MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | claimed |
| EP-1931637-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PainCeptor Pharma Corp. (CA) | 2008-06-18 | — | — | EP | claimed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | claimed |
| WO-2007030940-A2 | METHODS OF MODULATING NEUROTROPHIN-MEDIATED ACTIVITY | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-03-22 | — | — | WO | claimed |
| US-7579468-B2 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-08-25 | — | — | US | disclosed |
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | PAINCEPTOR PHARMA CORPORATION (CA) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093474-A1 | Methods of modulating neurotrophin-mediated activity | NGF, BDNF, NTRK2 | FTO 4015/4885PABPC1 3436/4885MEN1 3865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.